G
Greenwich LifeSciences
GLSI
15.340
USD
-0.53
(-3.34%)
مغلق
حجم التداول
476
الربح لكل سهم
0
العائد الربحي
0
P/E
-17
حجم السوق
174,560,992
الأخبار
العنوان: Greenwich LifeSciences
القطاع: Healthcare
الصناعة: Biotechnology
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.